Printer Friendly

Japan : Daiichi Sankyo Initiates Phase 1 Study of DS-1062 in Patients with Advanced Non-Small Cell Lung Cancer.

Daiichi Sankyo Company, Limited announced the first patient has been dosed in a phase 1 study assessing the safety and tolerability of DS-1062, an investigational TROP2-targeting antibody drug conjugate (ADC), in patients with unresectable advanced non-small cell lung cancer (NSCLC) who are refractory to or have relapsed following standard treatment or for whom no standard treatment is available.

With the discovery of driver genes and introduction of targeted therapies, there has been improvement in patient outcomes for certain types of NSCLC. However, for patients with unresectable advanced NSCLC, there is still a need for new therapeutic strategies as the five-year survival rates for patients with advanced stages of NSCLC are low.

DS-1062 is designed to target and deliver chemotherapy inside cancer cells expressing trophoblast cell-surface antigen 2 (TROP2), which is overexpressed in many cancers including NSCLC. Overexpression of TROP2 is a driver in cancer growth and has been associated with decreased patient survival, increased tumor aggressiveness, metastasis, and drug resistance in several tumor types.

We are initially focusing on evaluating DS-1062 in patients with advanced NSCLC with potential expansion into other tumor types depending on the results of this early critical test in a study designed to provide evidence supporting unique properties of this particular TROP2 ADC construct, said Antoine Yver, MD, MSc, Executive Vice President and Global Head, Oncology Research and Development, Daiichi Sankyo. With the initiation of this study of DS-1062, we move our third ADC into the clinic and continue to investigate the potential of the smart delivery of chemotherapy in various cancers including lung, breast and gastric cancer.

[c] 2018 Al Bawaba ( Provided by SyndiGate Media Inc. ( ).

COPYRIGHT 2018 SyndiGate Media Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Mena Report
Date:Feb 24, 2018
Previous Article:United States : U.S. TSA tests facial recognition and enhanced body scanner technology at LAX.
Next Article:Japan : Drone School for Training Drone Pilots to Open in April, Recruitment of Students Starts Now.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters